Spyre Therapeutics annual revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Spyre Therapeutics Revenue Growth & History (SYRE)
Spyre Therapeutics reported $0 in revenue for fiscal 2025.
View full Spyre Therapeutics company overviewSpyre Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | −$886,000 | −100.00% |
| 2023 | 2023-12-31 | $886,000 | −$1.4M | −61.96% |
| 2022 | 2022-12-31 | $2.3M | −$16.4M | −87.57% |
| 2021 | 2021-12-31 | $18.7M | $18.7M | — |
| 2020 | 2020-12-31 | $0 | $0 | — |
| 2019 | 2019-12-31 | $0 | −$3.9M | −100.00% |
| 2018 | 2018-12-31 | $3.9M | −$1.3M | −25.30% |
| 2017 | 2017-12-31 | $5.2M | $577,000 | +12.47% |
| 2016 | 2016-12-31 | $4.6M | — | — |
Spyre Therapeutics quarterly revenue
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | — | — |
| Q4 2025 | 2025-12-31 | $0 | $0 | — |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | $0 | — |
| Q4 2024 | 2024-12-31 | $0 | $0 | — |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q2 2024 | 2024-06-30 | $0 | −$688,000 | −100.00% |
| Q1 2024 | 2024-03-31 | $0 | −$198,000 | −100.00% |
| Q4 2023 | 2023-12-31 | $0 | −$168,000 | −100.00% |
| Q3 2023 | 2023-09-30 | $0 | −$174,000 | −100.00% |
| Q2 2023 | 2023-06-30 | $688,000 | $63,000 | +10.08% |
| Q1 2023 | 2023-03-31 | $198,000 | −$1.2M | −85.46% |
| Q4 2022 | 2022-12-31 | $168,000 | −$3.5M | −95.39% |
| Q3 2022 | 2022-09-30 | $174,000 | −$1.2M | −87.56% |
| Q2 2022 | 2022-06-30 | $625,000 | −$13.1M | −95.44% |
| Q1 2022 | 2022-03-31 | $1.4M | $1.4M | — |
| Q4 2021 | 2021-12-31 | $3.6M | — | — |
| Q3 2021 | 2021-09-30 | $1.4M | — | — |
| Q2 2021 | 2021-06-30 | $13.7M | — | — |
| Q1 2021 | 2021-03-31 | $0 | — | — |
| Q4 2019 | 2019-12-31 | $0 | $0 | — |
| Q3 2019 | 2019-09-30 | $0 | $0 | — |
| Q2 2019 | 2019-06-30 | $0 | −$2.4M | −100.00% |
| Q1 2019 | 2019-03-31 | $0 | −$1.5M | −100.00% |
| Q4 2018 | 2018-12-31 | $0 | −$1.5M | −100.00% |
| Q3 2018 | 2018-09-30 | $0 | −$1.3M | −100.00% |
| Q2 2018 | 2018-06-30 | $2.4M | $899,000 | +60.78% |
| Q1 2018 | 2018-03-31 | $1.5M | $528,000 | +53.77% |
| Q4 2017 | 2017-12-31 | $1.5M | — | — |
| Q3 2017 | 2017-09-30 | $1.3M | — | — |
| Q2 2017 | 2017-06-30 | $1.5M | — | — |
| Q1 2017 | 2017-03-31 | $982,000 | — | — |
Spyre Therapeutics revenue growth trends
Spyre Therapeutics's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Spyre Therapeutics source filings ↗